Adaptive Biotechnologies Corp vs Rockwell Automation — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Rockwell Automation trades at $450 (market cap $49.64B). The key difference: Rockwell Automation is far larger — about 12.3× Adaptive Biotechnologies Corp's market cap, and Rockwell Automation pays a 1.23% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ROK | |
|---|---|---|
Market Cap | $4.04B | $49.64B |
Sector | Health | Industrials |
52-Week High | $25.45 | $495.08 |
52-Week Low | $12.30 | $333.75 |
Enterprise Value | $4.10B | $52.77B |
Dividend Yield | — | 1.23% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →